tiprankstipranks

Peter A. Thompson Insider Profile

11 Followers
Peter A. Thompson, Director at Adaptimmune Therapeutics, holds 8.29M shares in ARS Pharmaceuticals (Ticker: SPRY), holds 0.00 shares in Alpine Immune Sciences (Ticker: ALPN), holds 14.76M shares in Edgewise Therapeutics (Ticker: EWTX). Most recently, Peter A. Thompson Sold ― shares of ARS Pharmaceuticals on Aug 28, 2024 for an estimated value of 1.09M.
tipranks
Peter A. Thompson

Peter A. Thompson
Adaptimmune Therapeutics (ADAP)
Director

Ranked #3,880 out of 99,797 Corporate Insiders

Profitable Transactions

55%
16 out of 29 Profitable Transactions

Average Return

+18.10%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$598M
75.98%
15.50%
5.80%
2.20%
0.52% Others
A breakdown of Peter A. Thompson's holdings

Insider Roles

Edgewise Therapeutics
(EWTX)
Director, Ten Percent Owner
ARS Pharmaceuticals
(SPRY)
Director
Corvus Pharmaceuticals
(CRVS)
Director, Ten Percent Owner
Janux Therapeutics Inc
(JANX)
Director
+3 other positions
Roles that Peter A. Thompson holds in companies

Most Profitable Insider Trade

Stock:
Adaptimmune Therapeutics
(ADAP)
Rating:Informative Buy
Date:Mar 28, 2017 - Mar 28, 2018
Return:+128.10%
The most profitable trade made by Peter A. Thompson

Peter A. Thompson's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Adaptimmune Therapeutics
Jun 06, 2018
Director
Informative Sell
253.63K
$2.96M
ALPN
Alpine Immune Sciences
May 20, 2024
Uninformative Sell
$0.00
Corvus Pharmaceuticals
Sep 22, 2021
Director, Ten Percent Owner
Informative Sell
6.76M
$34.65M
~THOR
Thoratec Corp
Dec 13, 2018
Uninformative Buy
$337.59M
THOR
Synthorx
Jan 24, 2020
Uninformative Sell
361.51M
$0.00
PRVL
Prevail Therapeutics
Jun 26, 2019
Uninformative Buy
$317.92M
PMV Pharmaceuticals
Sep 29, 2020
Director, Ten Percent Owner
Uninformative Buy
$171.06K
ARS Pharmaceuticals
Aug 28, 2024
Director
Informative Sell
1.09M
$92.67M
DBTX
Decibel Therapeutics
Feb 19, 2021
Uninformative Buy
$4.34M
Edgewise Therapeutics
Jan 25, 2024
Director, Ten Percent Owner
Informative Buy
5.00M
$454.19M
Janux Therapeutics Inc
Dec 30, 2021
Director
Informative Sell
820.12K
$13.13M
Anthera Pharmaceuticals
Director
$0.00
MRTX
Mirati Therapeutics
$0.00
List of latest transactions for each holding click on a transaction to see Peter A. Thompson's performance on stock

Peter A. Thompson insider profile FAQ

What is the percentage of profitable transactions made by Peter A. Thompson?
The percentage of profitable transactions made by Peter A. Thompson is 55%.
    What is the average return per transaction made by Peter A. Thompson?
    The average return per transaction made by Peter A. Thompson is 18.10%.
      What stocks does Peter A. Thompson hold?
      Peter A. Thompson holds: ADAP, ALPN, CRVS, ~THOR, THOR, PRVL, PMVP, SPRY, DBTX, EWTX, JANX, ANTH, MRTX stocks.
        What was Peter A. Thompson’s latest transaction?
        Peter A. Thompson latest transaction was an Informative Sell of $1.09M.
          What was Peter A. Thompson's most profitable transaction?
          Peter A. Thompson’s most profitable transaction was an Informative Buy of ADAP stock on March 28, 2017. The return on the trade was 128.10%.
            What is Peter A. Thompson's role in Adaptimmune Therapeutics?
            Peter A. Thompson's role in Adaptimmune Therapeutics is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.